They reported that high-grade serous ovarian cancer is characterized by TP53 mutations in almost all tumors (96%); and a low prevalence but statistically significant recurrent somatic mutations in nine further genes including NF1, BRCA1, BRCA2, RB1, and CDK12. This evidence concerns the gene BRCA2 and ovarian serous adenocarcinoma.